A clinical study of nedaplatin combined with paclitaxel in treatment for advanced non-small cell lung cancer

HUANG Zhang-zhou,ZHUANG Wu,HUANG Cheng,HUANG Yun-jian

DOI: https://doi.org/10.3969/j.issn.1673-7555.2012.09.001

2012-01-01

Abstract:Objective To observe the safety and efficacy of nedaplatin plus paclitaxel in treatment of advanced non-small cell lung cancer(NSCLC).Methods Patients with NSCLC,no matter weather previously treated,either stage ⅢB with pleural effusion or stage Ⅳ,were enrolled if they had a performance status of 0~2,and had adequate organ function.The respectively doses of nedaplatin day 1 and paclitaxel days 1 were 80 mg/m2 and 175 mg/m2,repeated every 21 days.Results 33 patients got the above regimen for at least 2 cycles,of them,17(The initial treatment group)were untreated before and 16(Retreatment group)had previously received chemotherapy.The overall response rate were 41.1% vs 31.3%,and the median survival time were 425 days vs 343 days in The initial treatment group and Retreatment group respectively.The overall rates of neutropenia and thrombocytopenia were 65.5% and 19% in all 33 courses,calculated by course.There were no treatment-related deaths.Conclusion Nedaplatin combined with paclitaxel is an effective and safe treatment regimen for advanced NSCLC patients,even in those resistant to cisplatin.